|
Feb 12
|
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
|
|
Oct 2
|
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
|
|
Oct 1
|
Replimune to Present at Two Upcoming Investor Conferences
|
|
Sep 5
|
Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
|
|
Jun 3
|
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 16
|
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
|
|
Apr 7
|
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
|
|
Apr 4
|
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 26
|
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
|
|
Mar 11
|
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
|
|
Mar 8
|
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
|
|
Mar 6
|
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
|
|
Mar 5
|
Replimune to Present at Three Upcoming Investor Conferences
|
|
Dec 7
|
An Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% Undervalued
|
|
Dec 5
|
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
|